Australia - English - Department of Health (Therapeutic Goods Administration)

galderma australia pty ltd - clobetasol propionate, quantity: 0.05 % w/v - application - excipient ingredients: polyquaternium-10; ethanol; purified water; citric acid monohydrate; coco-betaine; sodium laureth sulfate; sodium citrate dihydrate - topical treatment of moderate to severe scalp psoriasis in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

galderma australia pty ltd - clobetasol propionate -

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - clobetasol propionate 0.5 mg/g;  ;  ;   - shampoo - 0.5 mg/g - active: clobetasol propionate 0.5 mg/g       excipient: citric acid monohydrate coco-betaine ethanol polyquaternium-10 purified water sodium citrate dihydrate sodium laureth sulfate - the topical treatment of moderate to severe scalp psoriasis.

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

galderma laboratories s.a. (pty) ltd - shampoo - see ingredients - each 1,0 g cream contains clobetasol propionate 0,5 mg

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - clobetasol propionate (unii: 779619577m) (clobetasol - unii:adn79d536h) - clobetasol propionate 0.05 ml in 100 ml - clobex® (clobetasol propionate) lotion, 0.05% is a super-high potent corticosteroid formulation indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses only in patients 18 years of age or older (see precautions). treatment should be limited to 2 consecutive weeks. the total dosage should not exceed 50 g (50 ml or 1.75 fl.oz.) per week. for the treatment of moderate to severe plaque psoriasis, localized lesions (less than 10% body surface area) that have not sufficiently improved after the initial 2-week treatment with clobex® (clobetasol propionate) lotion, 0.05% may be treated for up to 2 additional weeks. any additional benefits of extending treatment should be weighed against the risk of hpa axis suppression before prescribing for more than 2 weeks. patients should be instructed to use clobex® (clobetasol propionate) lotion, 0.05% for the minimum amount of time necessary to achieve the desired results (see precautions). use in patients

New Zealand - English - Medsafe (Medicines Safety Authority)

obex medical ltd - meglumine ioxaglate 39.3%{relative} (gives 320mg iodine/ml); sodium ioxaglate 19.65%{relative} - solution for injection - 320 mg/ml - active: meglumine ioxaglate 39.3%{relative} (gives 320mg iodine/ml) sodium ioxaglate 19.65%{relative} excipient: sodium calcium edetate, hydrate water for injection - low osmolar x-ray contrast medium for the opacification of the vascular system, urinary tract, joints and female genital tract. hysterosalpingography

New Zealand - English - Medsafe (Medicines Safety Authority)

obex medical ltd - iodised oil 38%{relative} (eqv to 48% w/v iodine);   - solution for injection - 38% w/w - active: iodised oil 38%{relative} (eqv to 48% w/v iodine)   - in diagnostic radiology lipiodol ultra fluid is used in lymphography, hysterosalpingography in women undergoing infertility workup and sialography.

New Zealand - English - Medsafe (Medicines Safety Authority)

obex medical ltd - meglumine gadoterate 377 mg/ml equivalent to to 279.32 mg/ml gadoteric acid (0.5 mmol/ml) - solution for injection - 377 mg/ml - active: meglumine gadoterate 377 mg/ml equivalent to to 279.32 mg/ml gadoteric acid (0.5 mmol/ml) excipient: meglumine water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

obex medical ltd - gadoteric acid 279.3 mg/ml (0.5mmol/ml);   - solution for injection - 0.5 mmol/ml - active: gadoteric acid 279.3 mg/ml (0.5mmol/ml)   excipient: meglumine water for injection - magnetic resonance imaging for: - cerebral and spinal disease - diseases of the vertebral column - other whole-body pathologies (including angiography of the non-coronary arteries)

New Zealand - English - Medsafe (Medicines Safety Authority)

obex medical ltd - gadoteric acid 279.32 mg/ml ((0.5mmol/ml));  ;  ;   - solution for injection - 0.5 mmol/ml - active: gadoteric acid 279.32 mg/ml ((0.5mmol/ml))       excipient: meglumine water for injection - magnetic resonance imaging for: - cerebral and spinal disease - diseases of the vertebral column - other whole-body pathologies (including angiography of the non-coronary arteries)